Neos therapeutics, inc. (NEOS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenues:
Net product sales

64,649

49,988

27,132

10,033

3,792

-

-

Net product sales

-

-

-

-

-

316

-

Manufacturing

-

-

-

-

-

113

137

Profit sharing

-

-

-

-

-

169

226

Development

-

-

-

-

-

160

681

Net sales

-

-

-

-

-

758

1,044

Cost of goods sold

25,123

26,928

14,030

11,734

5,929

3,391

2,534

Gross profit

39,526

23,060

13,102

-1,701

-2,137

-2,633

-1,490

Research and development expenses

8,582

8,508

8,957

12,207

11,691

10,574

9,974

Selling and marketing expenses

28,122

44,133

46,881

49,291

5,672

229

153

General and administrative expenses

13,237

13,915

13,805

12,625

7,078

5,036

5,471

Loss from operations

-10,415

-43,496

-56,541

-75,824

-26,578

-18,472

-17,088

Interest expense

8,009

8,974

10,085

6,937

-

-

-

Interest expense

-

-

-

-

-3,721

-2,520

-2,115

Loss on debt extinguishment

-

-

-

-1,187

-

-445

-

Other (expense) income, net

1,533

795

854

1,197

-482

837

603

Loss before income taxes

-16,891

-51,675

-65,772

-

-

-

-

Income tax expense (benefit)

11

-

-

-

-

-

-

Change in fair value of earnout and warrant liabilities

-

-

-

-

-

249

-

Net loss from continuing operations

-

-

-

-

-

-

-18,600

Loss from discontinued operations, including $544 of impairment charges in 2013

-

-

-

-

-

-

-437

Net loss

-16,902

-51,675

-65,772

-82,751

-30,781

-20,849

-19,037

Net loss from continuing operations

-

-

-

-

-

-

-18,600

Preferred stock accretion to redemption value

-

-

-

-

1,169

1,118

1,227

Preferred stock dividends

-

-

-

-

1,221

2,185

2,185

Net loss from continuing operations attributable to common stock

-

-

-

-

-

-

-22,012

Loss from discontinued operations, including $544 of impairment charges in 2013

-

-

-

-

-

-

-437

Net loss

-16,902

-51,675

-65,772

-82,751

-30,781

-

-19,037

Preferred Stock Accretion to Redemption Value

-

-

-

-

1,169

-

1,227

Preferred Stock Dividends

-

-

-

-

1,221

-

2,185

Net loss attributable to common stock

-

-

-

-

-33,171

-24,152

-22,449

Weighted average common shares outstanding used to compute net loss per share, basic and diluted

49,723

32,288

24,751

16,052

7,581

876

788

Net loss per share from continuing operations attributable to common stock

-

-

-

-

-

-

-27.90

Loss per share from discontinued operations

-

-

-

-

-

-

-0.55

Net loss per share of common stock, basic and diluted

-0.34

-1.60

-2.66

-5.16

-4.38

-27.56

-28.45